Advent Venture Partners

Moximed focuses on enhancing care for patients suffering from osteoarthritis, particularly through the MISHA Knee System. This system offers an outpatient treatment option for those who have not found relief from other therapies and are not candidates for knee replacement. The company aims to improve patients' quality of life by addressing their specific needs and challenges.

MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.

Wondr Medical provides a platform that connects health professionals all over the world. The company's goal is to speed up discovery, innovation, and collaboration across the global health network. It was established in 2016 and is headquartered in London, England.

Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, and bioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal.

Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Wiz is a cybersecurity company that allows companies to find security issues in public cloud infrastructure. It has designed the first cloud-native visibility solution for enterprise security teams that analyzes the entire cloud environment to deliver a 360° view of security risks across clouds, containers, and workloads. The solution dives deep into risks with actionable, graph-based analysis, and all completely agentless.

Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.

Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology.

Rappta Therapeutics is a lead-optimization stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.

PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation. The company is modulating oncogene translation to dramatically improve cancer patient outcomes. Their precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics. PIC Therapeutics was founded in 2016 and is headquartered in Natick, Massachusetts, United States.

Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.

KaNDy Therapeutics is a provider of bio-technical research and development services intended to offer treatment for common, chronic debilitating female sex hormone-related conditions. The company's services offer non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment and reduce symptoms of hormone-related conditions.

Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in 2009 and Based in Orlando, Florida.

Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics.

Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted. The company was founded in 2015 and is headquartered in Natick, Massachusetts, United States.

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Capella Bioscience engages in the discovery and development of monoclonal antibodies (mAbs). It focuses on the employment of proprietary technologies to discover, develop, and commercialize medicines based on mAbs therapeutics for oncology, autoimmune, and other diseases independently, as well in collaboration with biotechnology and academic partners

Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in 2009 and Based in Orlando, Florida.

Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in 2009 and Based in Orlando, Florida.

Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories. ACHICA, the luxury flash-sale business, and baby specialist Kiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.

gmp-orphan (GMPO), it is their mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Their experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission.

Calcico is a venture backed biotechnology company focused on the development of novel CRAC channel inhibitors. The company aims to develop selective small molecules to treat a range of inflammatory and autoimmune conditions where there is clear evidence linking CRAC to human disease. Calcico is an Oxford based start up which was formed in April 2012 and funded by Advent Life Sciences and Touchstone Innovations. The company has developed proprietary ‘know-how’ comprising novel systems for selective CRAC channel screening and molecule characterisation. This puts us in a unique position to achieve the goal of potent and selective CRAC channel inhibition, which has so far eluded pharmaceutical companies.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in 2009 and Based in Orlando, Florida.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in 2009 and Based in Orlando, Florida.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories. ACHICA, the luxury flash-sale business, and baby specialist Kiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Avidex is an award-winning, full service audiovisual firm. An innovative leader in the design, integration, project management, equipment procurement and support services of audiovisual solutions for commercial and healthcare clients throughout the U.S. Avidex also offers a broad range of equipment rental and show services. Avidex successfully partners with architects, contractors, consultants, educators and executives to create boardrooms, videoconference rooms, auditoriums, training facilities, digital signage and many additional projects that incorporate audiovisual needs. With a current staff of over 130 employees, the people at Avidex have the background and knowledge to provide you with the best possible experience in implementing audiovisual and multimedia technologies. Over the past 10 years Avidex has successfully completed many International jobs in more than a dozen different countries ranging from Europe to Asia and has completed jobs in over 26 states. Avidex is a true single source for all audiovisual needs.

NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.

CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

Headquartered in the Bioscience Incubator at Manchester University in the UK, CN Creative provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. It has developed a distinctive portfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. CNC's diverse products include QuitDirect, an NHS-accredited supplier of comprehensive smoking cessation services, the Intellicig® electronic cigarette, ECOpure proprietary high purity nicotine preparations and NRT Direct, which provides traditional nicotine replacement therapy products and patient support services to publicly and privately sponsored smoking cessation programmes. CNC's Nicadex(TM) electronic inhaler nicotine replacement therapy product is in clinical development for use as part of medically supervised smoking cessation programmes.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories. ACHICA, the luxury flash-sale business, and baby specialist Kiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Ampla Pharmaceuticals designs and develops biopharmaceutical drugs. The company was incorporated in 2006 and is based in La Jolla, California.

Vitrue offers the industry’s most scalable and secure cloud-based social marketing solution, enabling brands to harness the full marketing potential of social on Facebook, Twitter, Google+, YouTube and emerging platforms. The award-winning Vitrue SRM platform collectively manages more than one billion social relationships in over 100 countries across more than 4,500 social accounts for its clients. For more information, visit www.vitrue.com.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.

Cellnovo Group SA is a medical technology company based in Paris, France, that focuses on developing and marketing innovative mobile diabetes management systems. Its flagship product includes a cordless micro-pump for insulin administration, an integrated activity monitor, and a cellular-enabled wireless touchscreen handset that connects securely to servers for real-time data access. This system allows users to manage insulin injections effectively while enabling family members and healthcare professionals to monitor the patient's condition remotely. The company aims to empower individuals with diabetes by providing tools that simplify management and enhance their quality of life. Cellnovo markets its products through a direct sales force in the United Kingdom and France, as well as through international distributors. Additionally, it has partnered with Diabeloop SA to develop an artificial pancreas solution, further expanding its commitment to innovative diabetes care. The company was incorporated in 2014 and seeks to transform diabetes management through thoughtful design and modern technology.

Pathwork Diagnostics is based in Redwood City, California. The company develops and delivers innovative molecular diagnostics for oncology. The Pathwork Tissue of Origin Test for frozen tissue was the first to receive FDA clearance for a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastic cancer.

Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

AmberFin enables content owners to maximize the value of their TV, film and video content, from capture through to distribution, while increasing revenues, reducing costs, saving time and eliminating incompatibility issues. AmberFin iCR, with four-time Emmy-award winning technology, plays a key role in turning the content that owners have into the content their customers want. As an open standards, future proof platform that digitizes and transforms new and archived content, AmberFin iCR delivers the best quality pictures at smaller file sizes across multiple delivery platforms, including the Internet, VoD, TV, mobile and other small screen devices.

OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

Farfetch operates an online luxury fashion retail platform that connects various independent boutiques worldwide. Founded in 2008 by Jose Neves and headquartered in London, the company offers a wide range of products, including bags, coats, dresses, jackets, jewelry, swimwear, trousers, shoes, knitwear, suits, shorts, and accessories for women, men, and children. Farfetch's modular technology platform is designed to meet the complex needs of consumers and luxury sellers, featuring an API-enabled proprietary technology stack that supports applications, services, and data management. Additionally, Farfetch has a dedicated division, Farfetch China, which focuses on enhancing connections within the luxury fashion industry in that market.

Avila Therapeutics designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation.

Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.

Oxagen Limited, a biopharmaceutical company, provides drug discovery and development solutions. It offers molecule drugs for the treatment of asthma, autoimmune disease, inflammatory bowel, psoriasis, allergy, and rheumatoid arthritis diseases. Oxagen Limited was founded in 1997 and is based in Abingdon, the United Kingdom.

Dailymotion is the video platform for discovering the events and ideas that keep the world surprising and diverse on four main topics: news, sports, music, and entertainment, as well as comedy skits, political debates, fashion shows, gaming live-streams and more. Launched in 2005, Dailymotion commands a global audience of 300 million entertainment-seekers who frequent the site and its dedicated mobile experience to surface the most relevant professional video content based on their unique tastes and interests. In 2017, Dailymotion relaunched its user experience and platform with a focus on premium content from trusted publishers. Global content partners include: Universal Music Group, Condé Nast Entertainment, Hearst Magazines Digital Media, Bloomberg Media, Group Nine Media, BBC News, VICE, Genius, Refinery29, Mic, Billboard/The Hollywood Reporter, Cheddar, Fuse Media, and FOX Deportes. Dailymotion’s world-class video player enables publishers to deliver flawless viewing experiences across 30,000+ channels and monetize their video investment on their owned media properties. The platform sees an average of 600,000 uploads per month. Dailymotion is owned by Vivendi, a Paris-based multinational media company. For more information, visit www.dailymotion.com.

The Fizzback Group are innovators in customer engagement. Founded in 2004, the award-winning Fizzback solution helps companies to listen, respond, and act in real-time to their customers' comments. Feedback captured at the point of experience is analyzed automatically using a unique artificial intelligence engine, driving relevant responses, prompting company action and providing powerful insight into the voice of a previously silent majority. Fizzback enables businesses to derive true economic benefits by increasing customer lifetime value and positive word-of-mouth.

Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.

Foundry is a company with a 20-year history that specializes in computer graphics, visual effects, and 3D design software. The company develops award-winning products that enhance visual experiences and is dedicated to collaborating with creative professionals worldwide. Foundry's software is widely utilized in the production of visual effects for feature films, video-on-demand content, television shows, and commercials, enabling artists and designers to create stunning visual sequences. Through its innovative technology, Foundry continues to play a significant role in the design and visual industries.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Qype is a social network based around user reviews of businesses and places. The site allows its users to browse a database of locations and see at a glance those which have been most favorably rated by the community. Members of the site can add new places to the existing database, rate and review businesses, add videos and photos and engage with the community via message boards, groups and messaging. Founded in 2005 by German entrepreneur Stephan Uhrenbacher, the site also has a mobile version which can enables users to locate the top rated place near to a specified location.

OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Wave energy is the future and Orecon is making that future today's reality. The oceans are a source of immense and limitless power. Orecon is here to harness that power and convert it into sustainable and affordable electricity. Orecon's MRC has been designed specifically to do this. It's a robust and reliable wave energy device that uses the best tried and tested components on the market. And it's clean because respecting the oceans is as important to us as releasing the power within them.

Wisair is a fabless semiconductor company providing single-chip based Ultra Wideband (UWB) and Wireless USB solutions for personal computing, consumer electronics, and mobile devices.

Moveme.com is a web site that provides free, instant quotes for moving related services.

Cellnovo Group SA is a medical technology company based in Paris, France, that focuses on developing and marketing innovative mobile diabetes management systems. Its flagship product includes a cordless micro-pump for insulin administration, an integrated activity monitor, and a cellular-enabled wireless touchscreen handset that connects securely to servers for real-time data access. This system allows users to manage insulin injections effectively while enabling family members and healthcare professionals to monitor the patient's condition remotely. The company aims to empower individuals with diabetes by providing tools that simplify management and enhance their quality of life. Cellnovo markets its products through a direct sales force in the United Kingdom and France, as well as through international distributors. Additionally, it has partnered with Diabeloop SA to develop an artificial pancreas solution, further expanding its commitment to innovative diabetes care. The company was incorporated in 2014 and seeks to transform diabetes management through thoughtful design and modern technology.

Audium is a fabless semiconductor company developing innovative, highly efficient audio power amplifier products for the Consumer Electronics market. The company was founded in March 2006 by Clyde Witchard and Huw Davies and is headquartered in Bristol, U.K.

Dailymotion is the video platform for discovering the events and ideas that keep the world surprising and diverse on four main topics: news, sports, music, and entertainment, as well as comedy skits, political debates, fashion shows, gaming live-streams and more. Launched in 2005, Dailymotion commands a global audience of 300 million entertainment-seekers who frequent the site and its dedicated mobile experience to surface the most relevant professional video content based on their unique tastes and interests. In 2017, Dailymotion relaunched its user experience and platform with a focus on premium content from trusted publishers. Global content partners include: Universal Music Group, Condé Nast Entertainment, Hearst Magazines Digital Media, Bloomberg Media, Group Nine Media, BBC News, VICE, Genius, Refinery29, Mic, Billboard/The Hollywood Reporter, Cheddar, Fuse Media, and FOX Deportes. Dailymotion’s world-class video player enables publishers to deliver flawless viewing experiences across 30,000+ channels and monetize their video investment on their owned media properties. The platform sees an average of 600,000 uploads per month. Dailymotion is owned by Vivendi, a Paris-based multinational media company. For more information, visit www.dailymotion.com.

BridgeCo offers processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Avila Therapeutics designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation.

Ubiquisys is a mobile communications company that designs and develops communications devices for mobile operators and consumers. It provides ZoneGate femtocell system, a small plug-and-play device that plugs into home or office broadband connection and provides 3G coverage in the home and office, as well as supports various mobile services. The company also offers convergence solutions to the wireless-wireline convergence technology market.

Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.

The Fizzback Group are innovators in customer engagement. Founded in 2004, the award-winning Fizzback solution helps companies to listen, respond, and act in real-time to their customers' comments. Feedback captured at the point of experience is analyzed automatically using a unique artificial intelligence engine, driving relevant responses, prompting company action and providing powerful insight into the voice of a previously silent majority. Fizzback enables businesses to derive true economic benefits by increasing customer lifetime value and positive word-of-mouth.

Founded in 2000, Echovox has built a unique gateway infrastructure offering premium SMS, Bulk and WAP billing in more than 20 different countries, connecting more than 100 mobile carriers worldwide and covering over 500 million subscribers. As an established leader in the mobile monetization space, Echovox enables large media companies, leading web players, mobile content providers and application developers to monetize their traffic though mobile transactions. Echovox was venture-backed by Advent Venture Partners and Newbury Ventures and launched Zong, world’s leading mobile payment solution, sold to Paypal in 2011. Strong of a 15 year experience in the mobile payment industry, our platform ECHONECTTM provides the best unified interface to the mobile world.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

OpenCloud, formed in 2000 is a privately funded company. It provides the telecommunications industry with a real-time Application Server for agile development, deployment and efficient management of person-to-person communications services across current and next generation network technology.

Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.